Cisplatin: Clinical Trials

2,014 trials of Cisplatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

854 completed, 355 unknown, 269 recruiting, 207 terminated. 2014 Phase 2, 266 Phase 1, 105 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22014Completed 854, Unknown 355, Recruiting 269, Terminated 207, Active not recruiting 142, Not yet recruiting 107, Withdrawn 68, Suspended 7, Enrolling by invitation 5
Phase 1266Completed 112, Terminated 47, Recruiting 37, Unknown 31, Withdrawn 18, Active not recruiting 15, Not yet recruiting 5, Suspended 1
Phase 3105Recruiting 25, Completed 22, Unknown 21, Active not recruiting 16, Not yet recruiting 9, Terminated 8, Suspended 2, Enrolling by invitation 1, Withdrawn 1

Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin

Trials (filtered) newest first · largest first

All 2,014 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma
Phase 2Not yet recruitingNorthwestern University442027-12-102026-06-10
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Tislelizumab - Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingNational Cheng-Kung University Hospital352027-06-012026-11-17
Chemo-embolization for Head and Neck Cancer
Cisplatin - SCCHN, Squamous Cell Carcinoma
Phase 2WithdrawnUniversity of Alabama at Birmingham2027-05-012025-04-27
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingMedical University of South Carolina382027-02-012026-11-10
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Telaglenastat, Radiation treatment, Cisplatin - Advanced Cervical Carcinoma, Cervical Cancer
Phase 2Not yet recruitingWashington University School of Medicine422026-12-312026-09-03
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC)
Phase 2WithdrawnNational Health Research Institutes, Taiwan2026-12-012026-07-02
Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma
Phase 2RecruitingUniversity of Miami202026-12-012026-08-26
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Phase 2Not yet recruitingSun Yat-sen University2982026-12-012026-10-27
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC)
Phase 2Not yet recruitingSun Yat-sen University2142026-12-012026-10-29
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer
Phase 2Not yet recruitingBristol-Myers Squibb802026-11-302026-10-13
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Befotinib, Pemetrexed + Cisplatin /Carboplatin - Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation
Phase 2RecruitingGuangzhou University of Traditional Chinese Medicine1242026-11-302026-11-04
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Phase 2RecruitingNational Cancer Institute (NCI)602026-11-222026-11-17
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)602026-11-222026-11-17
Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer
Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab - Head and Neck Cancer
Phase 2Not yet recruitingKevin Contrera1402026-11-152026-11-12
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.842026-11-012026-09-29
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma
Phase 2Not yet recruitingMehmet Akce292026-11-012026-11-04
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2Not yet recruitingMayo Clinic502026-11-012026-11-09
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer
Phase 2 / Phase 3RecruitingSichuan Baili Pharmaceutical Co., Ltd.1662026-10-212026-11-12

Showing 20 of 2014. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (298)  ·  Squamous Cell Carcinoma of Head and Neck (181)  ·  Head and Neck Neoplasms (160)  ·  Lung Neoplasms (143)  ·  Esophageal Neoplasms (106)  ·  Stomach Neoplasms (102)  ·  Uterine Cervical Neoplasms (87)  ·  Esophageal Squamous Cell Carcinoma (86)  ·  Urinary Bladder Neoplasms (75)  ·  Breast Neoplasms (67)  ·  Nasopharyngeal Carcinoma (66)  ·  Small Cell Lung Carcinoma (57)  ·  Neoplasms (56)  ·  Pancreatic Neoplasms (52)  ·  Neoplasm Metastasis (51)

Sponsors

National Cancer Institute (NCI) (71)  ·  Eli Lilly and Company (56)  ·  Memorial Sloan Kettering Cancer Center (55)  ·  Sun Yat-sen University (51)  ·  Fudan University (40)  ·  M.D. Anderson Cancer Center (35)  ·  European Organisation for Research and Treatment of Cancer - EORTC (27)  ·  Dana-Farber Cancer Institute (25)  ·  Radiation Therapy Oncology Group (23)  ·  Tianjin Medical University Cancer Institute and Hospital (22)  ·  SWOG Cancer Research Network (20)  ·  AstraZeneca (18)  ·  Hoffmann-La Roche (18)  ·  Alliance for Clinical Trials in Oncology (17)  ·  National Taiwan University Hospital (16)

Countries

United States (821)  ·  China (524)  ·  France (160)  ·  Spain (140)  ·  South Korea (131)  ·  Italy (129)  ·  Germany (127)  ·  Canada (125)  ·  United Kingdom (112)  ·  Taiwan (82)  ·  Belgium (77)  ·  Australia (70)  ·  Netherlands (64)  ·  Poland (56)  ·  Japan (53)

Top investigators

David H. Ilson, MD, PhD (6)  ·  Corey J. Langer, MD (5)  ·  David J. Adelstein, MD (5)  ·  Douglas Adkins, M.D. (5)  ·  Michele Reni, MD (5)  ·  Amar Gajjar, MD (4)

Results publications

PMID 25057165, PMID 29567784, PMID 33357481, PMID 19564532, PMID 22178121, PMID 23228446, PMID 25366678, PMID 26313683, PMID 28742685, PMID 28797458, PMID 29658856, PMID 30207593, PMID 30267838, PMID 30976202, PMID 30998813, PMID 31401903, PMID 32017652, PMID 33084020, PMID 33154826, PMID 33168398, PMID 33358660, PMID 34037241, PMID 35355438, PMID 38129778, PMID 38964333, PMID 40073837, PMID 40967259, PMID 10811668, PMID 11208820, PMID 11241082, PMID 11398890, PMID 11573045, PMID 11602624, PMID 11698646, PMID 11835236, PMID 11886723, PMID 11904735, PMID 12051882, PMID 12167786, PMID 12518365, PMID 12607634, PMID 12717353, PMID 12721251, PMID 12771884, PMID 1403051, PMID 14615449, PMID 14630682, PMID 14666038, PMID 14759776, PMID 14967461

NIH funding

U10CA032102 (22), 2023 (21), U10CA180820 (18), U10CA180868 (13), 2009 (12), P30CA043703 (11), 2018 (10), U10CA021115 (10), 2015 (9), 2016 (9), 2008 (8), 2014 (8), 2017 (8), 2025 (8), U10CA031946 (8)